Altimmune, Inc. (ALT) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
the bull case· 4
211
managers reporting a position in thirteen f filings
13fJun 30 '26+45.61%
change in shares held by the ten largest reporting managers
13fJun 30 '261 of 14
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '264
of the funds on file reporting a position in ALT
n-portas of Jun 30 '26the bear case· 3
0.23%
of State Street SPDR S&P Biotech ETF's assets, the largest fund weight on file
n-portJun 30 '266 of 8
recent reports where the move came in under the options implied range
earnings historyimplied vs realized18
managers whose positions together make up four fifths of the reported value
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 9 '26 report. Not a forecast, not advice.
Of the 6 companies Altimmune, Inc. moves with most closely, none share its SEC classification.
Measured against 124 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
Altimmune, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 3.26 at 5:00 am ET, low 3.20 at 2:15 pm ET.
tall tick = annual report · 1 on record
211 managers report a position worth $465.9M between them, and 18 of them hold 80% of it.
ALT (Altimmune, Inc.) has 0 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.